dolutegravir (tivicay) Report issue

Small molecule Approved FDA Fast Track FDA Priority Review FDA
AACT ChEMBL DrugBank Drug Central Drugs@FDA KEGG MeSH PubChem repoDB

Active Ingredient History

NOW
  • Now
Dolutegravir is an integrase inhibitor that is meant to be used as part of combination therapy for the treatment of HIV. Dolutegravir inhibits HIV integrase by binding to the integrase active site and blocking the strand transfer step of retroviral deoxyribonucleic acid (DNA) integration which is essential for the HIV replication cycle. Dolutegravir coadministered with dofetilide can result in potentially life-threatening adverse events.   NCATS

Chemistry

  • SMILES: C[C@@H]1CCO[C@H]2CN3C=C(C(=O)NCc4ccc(F)cc4F)C(=O)C(=C3C(=O)N12)O
  • InChIKey: RHWKPHLQXYSBKR-BMIGLBTASA-N
  • Mol. Mass: 419.38
  • ALogP: 1.35
  • ChEMBL Molecules:
    dolutegravir  
    dolutegravir sodium  
More Chemistry

Pharmacology

  • Mechanism of Action:
  • Multi-specific: Missing data
  • Black Box: No
  • Availability: Prescription Only
  • Delivery Methods: Oral
  • Pro Drug: No

Drug Pricing (per unit)

United States

$4.5562 - $62.0679

Australia

$16.3400
More Pricing Detail

Note: This drug pricing data is preliminary, incomplete, and may contain errors.

Combination drugs

( dolutegravir (tivicay), lamivudine (epivir) - other names: dolutegravir 50 mg / lamivudine 300 mg oral tablet [dovato], dolutegravir/lamivudine, dolutegravir/lamivudine 50 mg-300 mg oral tablet [dovato], dolutegravir/lamivudine as a single pill, dolutegravir / lamivudine oral tablet, dolutegravir plus lamivudine in a fdc )
|
( dolutegravir (tivicay), rilpivirine (edurant) )
|
( abacavir (ziagen), dolutegravir (tivicay), lamivudine (epivir) )

Alternative names

2h-pyrido(1',2':4,5)pyrazino(2,1-b)(1,3)oxazine-9- carboxamide, n-((2,4-difluorophenyl)methyl)-3,4,6,8,12,12a- hexahydro-7-hydroxy-4-methyl-6,8-dioxo-, (4r,12as)- | (4r,9as)-5-hydroxy-2-methyl-6,10-dioxo-3,4,6,9,9a,10-hexahydro-2h-1-oxa-4a,8a-diaza-anthracene-7-carboxylic acid- 2,4 difluorobenzylamide | abacavir sulfate / dolutegravir sodium / lamivudine | dolutegravir | dolutegravir sodium | dolutegravir sodium monohydrate | gsk1349572 | gsk 1349572 | gsk-1349572 | gsk1349572a | gsk 1349572a | s-349572 | s-gsk1349572 | tivicay | triumeq

Organizations (210)

Research & Development (200)

Organization Org Type FDA approvals Clinical Trials involvement Org ID Force Sort

Marketing (13)

Organization Org Type FDA approvals Clinical Trials involvement Org ID Force Sort

Indications (54)

Approved Indications (1)


 

HIV Infections

Experimental Indications - Clinical Trial Phases 1-4 (54)


 

Acquired Immunodeficiency Syndrome (Phase 4)

Adipose Tissue (Phase 4)

Alveolar Bone Loss (Phase 4)

Amyotrophic Lateral Sclerosis (Phase 3)

Antiretroviral Therapy, Highly Active (Phase 4)

Art (Phase 4)

Arthralgia (Phase 3)

Body Fat Distribution (Phase 4)

Body Weight Changes (Phase 4)

Bone Diseases, Metabolic (Phase 2)

Brain Injuries, Traumatic (Phase 2)

Cardiovascular Abnormalities (Phase 4)

Cardiovascular Diseases (Phase 4)

Contraception (Phase 4)

Cytomegalovirus Infections (Phase 4)

Diarrhea (Phase 1)

Drug Interactions (Phase 4)

Drug-Related Side Effects and Adverse Reactions (Phase 4)

Drug Resistance (Phase 4)

Drugs, Investigational (Phase 2/Phase 3)

Epstein-Barr Virus Infections (Phase 4)

Fatty Liver (Phase 4)

Healthy Volunteers (Phase 1)

Herpesvirus 8, Human (Phase 4)

HIV (Phase 4)

HIV-1 (Phase 4)

HIV-Associated Lipodystrophy Syndrome (Phase 4)

HIV Infections (Phase 4)

Infections (Phase 2/Phase 3)

Infectious Disease Transmission, Vertical (Phase 3)

Integrase Inhibitors (Phase 2)

Kidney Failure, Chronic (Phase 4)

Latent Tuberculosis (Phase 1)

Liver Diseases (Phase 4)

Lung Diseases (Phase 1)

Maintenance (Phase 4)

Malaria (Phase 1)

Medication Adherence (Early Phase 1)

Metabolic Side Effects of Drugs and Substances (Phase 2)

Obesity (Phase 4)

Organ Transplantation (Phase 4)

Osteoporosis (Phase 4)

Papillomaviridae (Phase 4)

Pregnancy (Phase 2/Phase 3)

Pregnancy Complications (Phase 3)

Renal Insufficiency (Phase 4)

Respiratory Tract Infections (Phase 1/Phase 2)

Sexually Transmitted Diseases, Viral (Phase 1)

Treatment Outcome (Phase 2)

Tuberculosis (Phase 4)

Tuberculosis, Multidrug-Resistant (Phase 1)

Tuberculosis, Pulmonary (Phase 2)

Vascular Diseases (Phase 4)

Weight Gain (Phase 4)

Overview

  • Highest Phase: Phase 4
  • # of Trials: 239
  • # of Trial Organizations: 200

Trials by Phase

Trial Phase Start Date Organizations Indications

Feedback

Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).

Report issue